No effect of copper supplementation on biochemical markers of bone metabolism in healthy young adult females despite apparently improved copper status

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Funding from the European Commission.

Who Took Part

PubMed indexes the participants as adults, women only.

A double-blind, placebo-controlled randomised repeat crossover Cu supplementation trial.

Sixteen healthy young adult females aged 20-28 y were recruited from among students at the RVAU.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

Each person switched between Copper (Supplement) and the comparison at some point, usually with a gap in between.

The study was conducted at the Royal Veterinary and Agricultural University (RVAU), Copenhagen, Denmark.

On the last 3 days of each dietary period 24 h urines were collected.

In addition, blood was collected on the last day of each dietary period.

What Was Measured

The subject headings attached to it are Biomarkers, Bone and Bones, Copper, Dietary Supplements, Erythrocytes and Superoxide Dismutase.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (European journal of clinical nutrition), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.